| Code | CSB-RA872537MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to NN-8828, designed to specifically target interleukin-21 (IL-21), a type I cytokine that plays a critical role in immune regulation. IL-21 is primarily produced by activated CD4+ T cells, particularly follicular helper T cells and Th17 cells, and signals through the IL-21 receptor to modulate both innate and adaptive immune responses. This cytokine influences B cell differentiation, antibody production, T cell proliferation, and NK cell cytotoxic function. Dysregulated IL-21 signaling has been implicated in various autoimmune disorders including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and type 1 diabetes, as well as in certain hematological malignancies.
NN-8828 is a therapeutic antibody originally developed for investigating IL-21 pathway inhibition in autoimmune and inflammatory conditions. This biosimilar provides researchers with a valuable tool for studying IL-21-mediated immune mechanisms, evaluating therapeutic intervention strategies in disease models, and exploring the cytokine's role in immune cell development and function. It serves as an important reagent for immunology research and preclinical studies investigating IL-21 biology.
There are currently no reviews for this product.